ATS View
한국어

OliX Pharmaceuticals KRX:226950KOSDAQ

올릭스 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h1
Articles, 7 days2
DART filings, 7 days0
Articles tracked55since Sep 11

In Q2 2026, OliX Pharmaceuticals reported an operating loss of ₩14.0bn. OliX Pharmaceuticals (올릭스) appeared in 2 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 19 with 3 articles. The most common catalyst was contracts & orders (1). It was most often mentioned alongside Peptron, G2gbio and Lemon Healthcare.

Filing signals Clinical trial filing 4 quarters of losses Screener

OliX Pharmaceuticals quarterly results consolidated, KRW

QuarterOperating profitNet income
Q2 2026−₩14.0bn−₩11.0bn
Q1 2026−₩10.8bn−₩9.8bn
Q4 2025 derived−₩8.5bn₩15.4bn
Q3 2025−₩8.3bn−₩8.7bn
Q2 2025−₩5.0bn−₩9.2bn
Q1 2025−₩8.2bn−₩13.3bn
Q4 2024 derived−₩7.6bn−₩12.2bn
Q3 2024−₩9.4bn−₩10.5bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

OliX Pharmaceuticals top stories 2 weeks, by number of outlets

  1. 1
    임상 반려에 기술 이전 감감무소식…올릭스, 펩트론 쇼크에 롤러코스터 타는 바이오株
    2 outlets · 2 articlesFirst report Oct 22 06:00 조선비즈Peptron
  2. 2
    레몬헬스케어 上…지투지바이오·올릭스, 빅파마 기술수출 기대감 ↑[바이오 맥짚기]
    1 outlets · 1 articlesFirst report Oct 23 13:01 이데일리Licensing dealLemon HealthcareG2gbio
  3. 3
    올릭스 주가, 10월 21일 장중 107,200원 9.84% 상승
    1 outlets · 1 articlesFirst report Oct 21 14:18 중앙이코노미뉴스
  4. 4
    올릭스, 비만신약 병용투여 체중 23% 감소…체지방 최대 93% 줄어
    1 outlets · 1 articlesFirst report Oct 19 12:16 메디코파마
  5. 5
    올릭스, 황반변성 치료제 뉴질랜드 임상 반려 두고 “절차상 소통 오류” 해명
    1 outlets · 1 articlesFirst report Oct 19 13:50 비즈한국
  6. 6
    임상 반려에 나흘째 흔들린 올릭스…OLX301A 재신청은?[바이오맥짚기]
    1 outlets · 1 articlesFirst report Oct 29 07:42 이데일리

Latest OliX Pharmaceuticals news Korean headlines